Document is current
Any future updates will be listed below
-
Authors
Adami, Giovanni https://orcid.org/0000-0002-8915-0755
Bartezaghi, Marta
Montanari, Filippo
Piccinelli, Anna
Pollastri, Francesco
Mastropaolo, Francesca
Giorgio, Francesco
Benini, Camilla
Fassio, Angelo
Rossini, Maurizio
Gatti, Davide
Fornari, Rachele
Viapiana, Ombretta
-
Funding
Funding for this research was provided by:
UCB Pharma Italy (PROTOCOL RWE0988)
Amgen (PROTOCOL RWE0988)
Università degli Studi di Verona
- License Information
-
More Information
Article History
Received: 5 March 2025
Accepted: 5 October 2025
First Online: 13 October 2025
Declarations
:
: The study was conducted according to the protocol RWE0988 approved by our local Ethics Committee, in accordance with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was collected for each participant.
: Patients provided consent for the publication of anonymized data.
: Giovanni Adami has received advisory board honoraria, consultancy fees, and/or speaker fees from Theramex, UCB, Lilly, Galapagos, Fresenius Kabi, Amgen, BMS, Abiogen, and Pfizer. Davide Gatti has received advisory board honoraria, consultancy fees, and/or speaker fees from Abiogen, Celgene, Eli-Lilly, Neopharmed-Gentili, Pfizer, and UCB. Maurizio Rossini reports advisory board honoraria, consultancy fees, and/or speaker fees from AbbVie, Eli-Lilly, Italfarmaco, Neopharmed-Gentili, Theramex, UCB, outside the submitted work. Ombretta Viapiana has received advisory board honoraria and speaker fees from Gilead, Fresenius Kabi, Biogen, Eli-Lilly, UCB, Abbvie, MSD, and BMS. Angelo Fassio reports personal fees from Abiogen, Novartis, and Neopharmed. Marta Bartezaghi and Rachele Fornari are employees of UCB. Filippo Montanari, Anna Piccinelli1, Francesco Pollastri, Francesca Mastropaolo, Francesco Giorgio, Camilla Benini have nothing to declare.
